ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22 Apr 2025 06:59:08 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 Mar 2025 07:00:05 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 Feb 2025 06:59:55 By Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 Feb 2025 06:50:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 Jan 2025 16:01:21 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 Jan 2025 16:30:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 Dec 2024 16:30:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 Nov 2024 09:45:01 By NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 Nov 2024 09:52:02 By NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 Nov 2024 08:10:41 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 Nov 2024 08:10:04 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

13 Nov 2024 09:53:10 By NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

11 Nov 2024 09:48:00 By NetDania Notify

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 Jul 2024 16:01:43 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire